-
EP4392457
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4392457
| EP4392457 - BISPECIFIC TETRAVALENT ANTIBODY TARGETING EGFR AND HER3 [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 31.05.2024 Database last updated on 06.11.2024 | |
| Former | The international publication has been made Status updated on 03.03.2023 | Most recent event Tooltip | 01.11.2024 | Change: Validation states | published on 04.12.2024 [2024/49] | 01.11.2024 | Change - extension states | published on 04.12.2024 [2024/49] | Applicant(s) | For all designated states Systimmune, Inc. 15318 NE 95th Street Redmond, WA 98052 / US | [2024/34] |
| Former [2024/27] | For all designated states Systimmune, Inc. 15318 NE 95th Street Redmond, WA 98052 / US | ||
| For all designated states Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. 139 Baili Road Wenjiang District Chengdu, Sichuan 611130 / CN | Inventor(s) | 01 /
GOULET, Dennis R. Redmond, Washington 98052 / US | 02 /
KHALILI, Jahan Kirkland, Washington 98034 / US | 03 /
RENSHAW, Blair Renton, Washington 98058 / US | 04 /
MAK, Nga Sze Amanda Mukilteo, Washington 98275 / US | 05 /
ZHU, Hai Bothell, Washington 98012 / US | 06 /
ZHU, Yi Chengdu, Sichuan / CN | [2024/27] | Representative(s) | Hobson, David James, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB | [2024/27] | Application number, filing date | 22862268.4 | 25.08.2022 | [2024/27] | WO2022US75445 | Priority number, date | US202163237033P | 25.08.2021 Original published format: US 202163237033 P | [2024/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2023028548 | Date: | 02.03.2023 | Language: | EN | [2023/09] | Type: | A2 Application without search report | No.: | EP4392457 | Date: | 03.07.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.03.2023 takes the place of the publication of the European patent application. | [2024/27] | Search report(s) | International search report - published on: | US | 06.04.2023 | Classification | IPC: | C07K16/30, C07K16/28, A61K39/395, A61P35/00 | [2024/27] | CPC: |
C07K16/2863 (EP,IL,KR,US);
A61K45/06 (US);
A61K47/6849 (US);
A61P35/00 (EP,IL,KR,US);
C07K16/32 (EP,IL,KR,US);
A61K2039/505 (KR);
C07K2317/31 (EP,IL,KR,US);
C07K2317/52 (EP,IL,KR);
C07K2317/55 (EP,IL,KR,US);
C07K2317/622 (EP,IL,KR,US);
C07K2317/64 (EP,IL);
C07K2317/73 (EP,IL,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/27] | Title | German: | BISPEZIFISCHER TETRAVALENTER ANTIKÖRPER GEGEN EGFR UND HER3 | [2024/27] | English: | BISPECIFIC TETRAVALENT ANTIBODY TARGETING EGFR AND HER3 | [2024/27] | French: | ANTICORPS TÉTRAVALENT BISPÉCIFIQUE CIBLANT EGFR ET HER3 | [2024/27] | Entry into regional phase | 25.03.2024 | National basic fee paid | 25.03.2024 | Search fee paid | 25.03.2024 | Designation fee(s) paid | 25.03.2024 | Examination fee paid | Examination procedure | 25.03.2024 | Examination requested [2024/27] | 16.10.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 23.08.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]US2010196265 (ADAMS GREGORY P [US], et al); | [A]US2016194399 (IRVING BRYAN ALLEN [US], et al); | [Y]US2016333105 (ADAMS RALPH [GB], et al); | [XYA]US2017073418 (GAO ZEREN [US], et al); | [Y]WO2021092266 (SYSTIMMUNE INC [US], et al) |